Long-term cardiology side effects of antitumor therapy in patients with hemoblastosis
https://doi.org/10.33667/2078-5631-2025-33-39-44
Abstract
The relevance of improving diagnostic methods, drug and radiation therapy contributes to an increase in the life expectancy of cancer patients including hemoblastosis. At the same time, the number of patients with various complications, including those from the cardiovascular system as a result of antitumor therapy, has increased. The identification of long-term toxic effects of antitumor therapy in patients with hemoblastosis is relevant due to the increased life expectancy of patients after treatment.
Objective: according to the literature, to evaluate the long-term side effects of cardiotoxic effects in patients with hemoblastosis who received antitumor treatment.
Material and methods. When writing a literature review, data were analyzed in specialized medical databases Pubmed, Scopus, Web of Science in patients with hemoblastosis from 1994 to 2024.
Results. Cardiotoxic side effects in patients with hemoblastosis as a result of antitumor therapy may occur in the long term years after treatment. This review is devoted to the analysis of the cardiotoxic effects of various forms of therapy on the heart in adults and children with hemoblastosis in the long-term period after treatment. The causes of side effects on the cardiovascular system are discussed, the molecular, genetic, and biochemical correlates of these disorders are described, and ways to prevent complications are considered. This, in turn, opens up opportunities for early detection and treatment of long-term complications in surviving patients. This will contribute to improving the quality of life of patients.
About the Authors
E. I. Kuznetsova
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Kuznetsova Elena I., Dr Bio Sci (habil.), researcher at Dept of Functional Diagnostics
Moscow
D. D. Tsyrenov
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Tsyrenov Damba D., PhD Med, cardiologist, head of Dept of Functional Diagnostics
Moscow
References
1. Aleskerova G. A., Shervashidze M. A., Popa A. V., Valiev T. T., Kurdyukov B. V., Bat’manova N.A., Mentkevich G. L. Results of treatment of acute lymphoblastic leukemia in children according to the ALL IC-BFM 2002 protocol. Oncopediatrics. 2016. Vol. 3. No. 4. Pp. 302–308. (In Russ.).
2. Valiev T. T., Popa A. V., Levashov A. S., Belyaeva E. S., Kulichkina N. S., Kurdyukov B. V., Ravshanova R. S., Mentkevich G. L. Non-Hodgkin’s lymphomas in children: 25 years of therapy. Clinical oncohematology. Fundamental research and clinical practice. 2016. T. 9. No. 4. P. 420–437. (In Russ.).
3. Baryakh E. A., Tyurina N. G., Vorobyov V. I., Gemdzhyan E. G., Mangasarova Y. K., Klyasova G. A., Kovrigina A. M., Obukhova T. N., Zvonkov E. E., Vernyuk M. A., Chervontseva A. M., Polyakov Yu. Yu., Misyurina A. E., Valiev T. T., Zherebtsova V. A., Magomedova A. U., Galstyan G. M., Yatskov K. V., Nesterova E. S., Vorobyov A. I. and others. Twelve years of experience in the treatment of Burkitt’s lymphoma according to the LB-M-04 protocol. Therapeutic archive. 2015. T. 87. No. 7. P. 4–14. (In Russ.).
4. Baryakh E. A., Valiev T. T., Yatskov K. V., Zvonkov E. E., Kremenetskaya A. M., Kravchenko S. K., Magomedova A. U., Galstyan G. M., Klyasova G. A., Drozhzhin A. A., Ryazanova I. B., Shulutko E. M., Obukhova T. N., Biryukova L. S., Shevelev A. A., Gretsov E. M., Gubkin A. V., Kaplanskaya I. B., Gotman L. N., Krasilnikova B. B. et al. Intensive therapy of Burkitt’s lymphoma: description of two clinical cases. Hematology and transfusiology. 2007. Vol. 52. No. 1. Pp. 41–43. (In Russ.).
5. Valiev T. T., Baryakh E. A. Evolution of views on the diagnosis and treatment of Burkitt’s lymphoma. Clinical oncohematology. Fundamental research and clinical practice. 2014. Vol. 7. No. 1. Pp. 46–56.
6. Vinogradova Yu.E., Lutsenko I. N., Kaplanskaya I. B., Vorobyov I. A., Samoylova R. S., Gorgidze L. A., Ryzhikova N. A., Valiev T. T., Gilyazitdinova E. A., Dzhulakyan U. L., Egorova E. K., Zvonkov E. E., Krasilnikova B. B., Magomedova A. U., Margolin O. V., Maryin D. S., Kremenetskaya A. M., Kravchenko S. K., Vorobyov A. I. Efficiency of therapy of various variants of anaplastic large T-cell lymphomas. Therapeutic archive. 2008. Vol. 80. No. 7. Pp. 33–37. (In Russ.).
7. Valiev T. T. Modern strategy for diagnosis and treatment of non-Hodgkin’s lymphomas in children. Abstract of a dissertation for the degree of Doctor of Medical Sciences / Russian Oncology Research Center named after N. N. Blokhin, Russian Academy of Medical Sciences. Moscow, 2014. (In Russ.).
8. Jain D, Russell RR, Schwartz RG et al. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions 2017 May;19(5):36. DOI: 10.1007/s11886–017–0846-x.
9. Zaeva G. E., Valiev T. T., Gavrilenko T. F., Moiseenko E. I., Medvedovskaya E. G., Mikhailova S. N., Sinyagina Yu. V. Remote consequences of therapy for malignant tumors in children: 35 years of clinical observations. Modern oncology. 2016. Vol. 18. No. 1. Pp. 55–60. (In Russ.).
10. Valiev T. T., Shervashidze M. A., Belysheva T. S. Evaluation of toxicity of therapy for acute lymphoblastic leukemia according to the ALL IC-BFM 2002 protocol. Oncohematology. 2022. Vol. 17. No. 3. Pp. 137–159. (In Russ.).
11. Sachuk O. V., Valiev T. T., Kravchenko N. E., Suetina O. A. Quality of life issues in children with lymphomas. MD-Onco. 2022. Vol. 2. No. 1. Pp. 65–73. (In Russ.).
12. Belyaeva E. S., Susuleva N. A., Valiev T. T. The importance of intensive chemotherapy for the treatment of children with advanced Hodgkin’s lymphoma. RMJ. Mother and Child. 2020. Vol. 3. No. 2. Pp. 149–153. (In Russ.).
13. Said R., Nickolich M., Lenihan D. J., Tsimberidou A. M. Cardiotoxicity of anticancer therapies // Cardio-Oncology: Clin. Overlap Cancer Heart Dis. 5 (February). 2017: 15–42.
14. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults Crit Rev Oncol Hematol. 1998 Jan;27(1):53–68. DOI: 10.1016/s1040-8428(97)10007-5.
15. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. (2020) 7:26. DOI: 10.3389/fcvm.2020.00026.
16. Hequet O., Le QH, Moullet I, Pauli E, et.al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–1871.
17. Dorokhina E. I., Magomedova A. U., Shevelev A. A., et al. Remote cardiotoxicity of highdose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma // Therapeutic archive 2015 No. 7 pp. 51–57. (In Russ.). DOI: 10.17116/terarkh201587751–57
18. Zeina N. Al-Mahayri, Mohammad M. AlAhmad, Bassam R. Ali. Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies? (Review). eCollection 2021. Oct 15:11:710163. DOI: 10.3389/fonc.2021.710163.
19. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629–2636.
20. Pepe A., Pizzino F., Gargiulo P., et al. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology // J. Cardiovasc. Med. (Hagerstown). 2016. Vol. 17, Suppl 1. P. S 45–54.
21. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review Ann Oncol 2002. 13(6):819–29. DOI: 10.1093/annonc/mdf167.
22. Haddy T.B, Adde M.A, Calla J. Mc, et al. Late effects in long-term survivors of high-grade non-Hodgkin’s lymphomas J Clin Oncol, 6 (1998), pp. 2070–2079
23. Zhang S., Liu X., Bawa-Khalfe T., et al. Identification of the molecular basis of doxorubicininduced cardiotoxicity Nat Med. 2012. 18. P. 1639–42. DOI:10.1038/nm.2919
24. Qiu S, Zhou T, Qiu B, Zhang Y, et al. Risk factors for anthracycline-induced cardiotoxicity. Front Cardiovasc Med. (2021) 8:736854. DOI: 10.3389/fcvm.2021.736854
25. Guryeva O. D., Savelyeva M. I., Valiev T. T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Russian Journal of Pediatric Hematology and Oncology. 2021. Vol. 8. No. 4. P. 60–70. (In Russ.).
26. Krajinovic M, Elbared J, Drouin S, Bertout L, et al. Polymorphisms of ABCC 5 and NOS 3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. (2016) 16:530–5. DOI: 10.1038/tpj.2015.63
27. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J. (2022) 43(41):4229–361. 10.1093/eurheartj/ehac244 14. Chang VY, Wang JJ. Pharmacogenetics of chemotherapy-induced cardiotoxicity. Curr Oncol Rep. (2018) 20:52. DOI: 10.1007/s11912-018-0696-8
28. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, et.al.Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30: 1042–1049.15.
29. Gimeno E, Gomez M, Gonzalez JR, Comin J, et al. NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. Leuk Res2011; 35: 715–720.
30. Ratosa I, Pantar MI. Cardiotoxicity of mediastinal radiotherapy. Pract Oncol Radiother. 2019 Nov-Dec;24(6):629–643. DOI: 10.1016/j.rpor.2019.09.002.
31. Bricker J. T., Green D. M., D’Angio G. J. Cardiac toxicity after treatment for childhood cancer. NY: Wiley-Liss, Inc, 1994.
32. Fajardo L. F, Berthrong M, Anderson R. E. Radiation pathology. Oxford University press, 2001; 165–80.
33. Mettier F. A, Upton A. S. Medical effects of ionizing radiation. Philadelphia, 1995; 430.
34. Curigliano G, Cardinale D, Suter T, et al3 Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7): vii155–vii166.
35. Aleman B.M P, Belt-Dusebout A.W, Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma Blood. 2007;109(5):1878–86. DOI: 10.1182/blood-2006-07-034405.
36. Groarke J D, Tanguturi VK, Hainer J et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes J Am Coll Cardiol 2015 17;65(6):573–83. DOI: 10.1016/j.jacc.2014.11.035
37. Heidenreich PA, Hancock SL, Lee BK., et.al. Asymptomatic cardiac disease following mediastinal irradiation J Am Coll Cardiol 2003 20;42(4):743–9. DOI: 10.1016/s0735–1097(03)00759-9.
38. Adams M. J., Lipsitz S. R. Colan S. D., et. al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J. Clin. Oncol 2004 Aug 1;22(15):3139–48. DOI: 10.1200/JCO.2004.09.109
39. Feoktistov R. I., Shchurova O. A., Abugova Yu.G., et al. Cardiotoxicity of chemoradiotherapy for Hodgkin’s lymphoma in children and adolescents. Oncohematology, No. 1 2010; (1): 31–36. (In Russ.).
40. Kulichkina N. S., Belyaeva E. S., Popa A. V., Valiev T. T., Odzharova A. A., Mentkevich G. L. The role of intermediate positron emission tomography combined with computed tomography in the treatment tactics of Hodgkin’s lymphoma in children. Modern oncology. 2017. Vol. 19. No. 3. P. 52–56. (In Russ.).
41. Podlesnikar T., Berlot B., Dolenc J., Goricar K., Marinko T. Radiotherapy-Induced Cardiotoxicity: The Role of Multimodality Cardiovascular Imaging. Front. Cardiovasc. Med. 2022;9:887705. DOI: 10.3389/fcvm.2022.887705.
42. Kravchenko N. E., Suetina O. A., Sachuk O. V., Valiev T. T. Mental health disorders in oncohematological diseases in children and adolescents. Medical alphabet. 2023. No. 17. P. 26–31. (In Russ.).
Review
For citations:
Kuznetsova E.I., Tsyrenov D.D. Long-term cardiology side effects of antitumor therapy in patients with hemoblastosis. Medical alphabet. 2025;(33):39-44. (In Russ.) https://doi.org/10.33667/2078-5631-2025-33-39-44
Views:
130
JATS XML
Email this article 